The Latest Research on Hormone Receptor-Positive (HR+) MBC
Hormone receptor-positive (ER+ and/or PR+) MBC is typically treated with hormone therapy plus other therapies. Read below for the latest research on treatments, including some discussed at the San Antonio Breast Cancer Symposium in December 2022, and related clinical trials for HR+ MBC, including an AKT inhibitor, oral selective estrogen receptor degraders (SERDs), CDK 4/6 inhibitors, and others.
Overview
- OncLive (Article and Video): HR+ MBC: Overview of Current Treatments
- Everyday Health: 6 Questions About HR-Positive, HER2-Negative MBC
- MedScape: Advances in HR+ MBC From SABCS
AKT Inhibitors
- OncLive (Article and Video): Targeting the PI3K/AKT/mTOR Pathway in HR+ MBC
- Healio: Capivasertib, an AKT Inhibitor, for HR+ MBC
- Current clinical trials: MBC Trials for AKT Inhibitors
Oral SERDs
- Metastatic Trial Talk: Oral SERDs
- Healio: Camizestrant, an Oral SERD, for HR+ MBC
- Healio: Elacestrant, an Oral SERD, and a CDK 4/6 Inhibitor for HR+ MBC
- Current clinical trials: MBC Trials for SERDs
CDK 4/6 Inhibitors
- Metastatic Trial Talk: CDK 4/6 Inhibitors
- Healio: Ribociclib, a CDK 4/6 Inhibitor, for HR+ MBC
- OncLive (Article and Video): Reducing Side Effects in People Receiving Ribociclib for HR+, HER2- MBC
- Current clinical trials: MBC Trials for CDK 4/6 Inhibitors
Protein Degraders
- OncLive: ARV-471, a Protein Degrader, in Estrogen Receptor-Positive, HER2-Negative MBC
- Current clinical trials: MBC Trials for ARV-471